ACOR News and Press, Acorda Therapeutics Inc. From 08/08/21

Acorda Therapeutics, Inc. (ACOR) Q2 2021 Earnings Conference Call August 5, 2021 04:30 PM ET Company Participants Tierney Saccavino - Executive Vice President-Corporate Communications Ron Cohen - Chief Executive Officer Conference Call Participants Muzamil Saleem - H.C. Wainwright Presentatio...

Acorda Therapeutics (NASDAQ:ACOR): Q2 Non-GAAP EPS of -$1.87; GAAP EPS of -$2.29 misses by $0.20. Revenue of $31.79M (-5.4% Y/Y) beats by $1.85M. Press Release For further details see: Acorda Therapeutics EPS misses by $0.20, beats on revenue

INBRIJA ® (levodopa inhalation powder) Q2 2021 net revenue of $6.4 million; 36% increase over Q2 2020 AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg Q2 2021 net revenue of $21.8 million Agreement to commercialize INBRIJA in Spain with Esteve Pharmac...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its second quarter 2021 update and financial results on Thursday, August 5 at 4:30 p.m. ET. To participate in the Webcast/Conference Call, please use the following pre-registration l...

Iterum Therapeutics plc (ITRM) -43% after announcing FDA’s Complete Response Letter for sulopenem.ATI Physical Therapy, Inc. (ATIP) -25% on Q2 earnings releaseNew Oriental Education & Technology Group Inc. (EDU) -24% provides update on new regulations.China...

Acorda Therapeutics continues to maneuver to set up for a potential turnaround in the coming years. The company recently announced a commercial partnership with Esteve Pharmaceuticals for INBRIJA in Spain. I expect additional European and Ex-U.S. partnerships are on the docket. Ac...

Gainers: [[NRXP]] +10.1%. [[PDD]] +6.6%. [[TLSA]] +6.3%. [[AFMD]] +4.4%. [[UXIN]] +3.8%.Losers: [[ACOR]] -3.8%. [[IPA]] -2.8%. [[SNCR]] -2.5%. [[PRVB]] -2.3%. [[INCY]] -3.3%. For further details see: NRXP, PDD, ACOR and IPA among after-hours movers

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re gearing up for one final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! Source: Shutterstock But hold up just a minute. Let’s r...

Acorda Therapeutics (ACOR) shares surge more than 27% post market after inking distribution and supply agreements with Esteve Pharmaceuticals to commercialize INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain.INBRIJA is indicated in the EU for th...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA ® 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU fo...